Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...
Clinical trial approval / initiation
Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for...
Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for...
AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital
AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and...
Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for Two Clinical Trials
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced two clinical trial approvals from the National...
Hutchison China Meditech Initiates Two Phase II Studies for HMPL-453 and Orpathys
China-based Hutchison China Meditech (HutchMed, NASDAQ: HCM, HKG: 0013) has announced that the first subjects...
Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B
Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases,...
Jacobio Pharma Receives Approval for Phase I/IIa Study of LIF mAb in Advanced Solid Tumors
China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to conduct a Phase...
CSPC Pharmaceutical Receives FDA Approval for Phase I Study of CPO301 in Lung Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
Shanghai Fosun Pharmaceutical Gets NMPA Approval for FCN-338 Phase II Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced receiving approval...
Changzhou Qianhong Bio-pharma Receives NMPA Approval for QHRD107 Phase II AML Study
China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced obtaining approval from the National...
Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a...
Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...
Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment...
Kintor Pharmaceutical Realigns Funds from COVID-19 Studies to Other Pipeline Candidates
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of...
CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008
Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Secure Clinical Trial Approvals for Solid Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...